BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-880@pharmaconomics
DTSTAMP:20260707T021221Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:GOSS Approval — seralutinib
DESCRIPTION:A final FDA approval decision on seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) is expected Mar 1\, 2027.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518xexx991xearni.htm\n\nTrack it: https://pharmaconomics.com/e/880
URL:https://pharmaconomics.com/e/880
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GOSS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR